StatPearls
- 1 January 2023
Abstract
Dapsone is indicated for a variety of conditions, both dermatologic and non-dermatologic. The FDA-approved indications are leprosy and dermatitis herpetiformis. The non-FDA-approved indications include a wide range of dermatoses and malaria and Pneumocystis (carinii) jiroveci prophylaxis and treatment. This activity reviews the mechanism of action, adverse event profile, toxicity, dosing, pharmacodynamics, and monitoring of dapsone, pertinent for interprofessional team members in treating conditions where dapsone is indicated.Keywords
This publication has 8 references indexed in Scilit:
- Update on the use of dapsone in dermatologyInternational Journal of Dermatology, 2020
- Re: Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009–2015Clinical Microbiology and Infection, 2019
- Use of Dapsone in the Treatment of Chronic Idiopathic and Autoimmune UrticariaJAMA Dermatology, 2019
- Efficacy of Systemic Dapsone Treatment for Pyoderma Gangrenosum: A Retrospective Review2018
- Neutrophilic dermatosis of the dorsal hands: response to dapsone monotherapyAnais Brasileiros de Dermatologia, 2018
- Two Cases of Dermatitis Herpetiformis Successfully Treated with Tetracycline and Niacinamide2018
- Leprosy cases with respiratory infection – Rule out tuberculosis simultaneously with dapsone syndromeIndian Journal of Pharmacology, 2018
- Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatmentCochrane Database of Systematic Reviews, 2014